This is a promotional email from Gilead Sciences intended for healthcare professionals only.
VEKLURY has now received a full marketing authorisation in Great Britain and Europe as a treatment for
SARS-CoV-2 infection, the virus that causes COVID-19.1
|
|
|
|
Dear Healthcare Professional,
We wish you an excellent 2023 and are pleased to inform you about the recent expansion of VEKLURY’s commissioning.
Based on the outcomes of the CARAVAN trial1* and the updated WHO COVID therapeutic guidelines†, VEKLURY’s three interim commissioning policies have been updated to expand their recommended use to more paediatric COVID-19 patients.
|
|
|
| VEKLURY®▼ (remdesivir): Expansion of its commissioning to more eligible COVID-19 patients2-4
|
|
|
|
|
|
| The three interim Clinical Commissioning Policies recommending the use of VEKLURY were updated on the 28 November 2022:
|
|
| FOR HOSPITALISED PATIENTS
|
| 1. Remdesivir for Patients Hospitalised due to COVID-19
|
Changes for VEKLURY:
now commissioned for adult and paediatric patients (at least 4 weeks of age and weighing at least 3kg)2
|
| Access the policy’s full details†
|
>
|
| 2. Treatment of Hospital-Onset COVID-19 in Adults and Children
|
Changes for VEKLURY:
now commissioned for eligible patients when they weigh 40kg or more (independently of age)3
|
| Access the policy’s full details†
|
>
|
|
|
|
|
| FOR NON-HOSPITALISED PATIENTS
|
| 3. Treatments for Highest Risk Non-Hospitalised Patients (Adult and Children) with COVID-19
|
Changes for VEKLURY:
now commissioned for eligible patients when they weigh 40kg or more (independently of age)4
|
| Access the policy’s full details†
|
>
|
|
|
|
|
|
|
| VEKLURY is indicated for the treatment of coronavirus disease 2019 (COVID-19) in:1
|
|
 |
Adults and paediatric patients (weighing at least 40kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19
|
|
|
|
 |
Adults and paediatric patients (at least 4 weeks of age and weighing at least 3kg) with pneumonia requiring supplemental oxygen (low- or high-oxygen or other non-invasive ventilation at the start of treatment)
|
|
|
|
|
To date, VEKLURY and generic remdesivir have been made available to approximatively 12 million COVID-19 patients globally and Gilead remains strongly committed to the continued review and exploration of its potential to help in this pandemic.5
If you’d like to know more about VEKLURY, please email UKMed.Info@gilead.com to contact the Gilead medical team directly.
|
|
|
|
Yours sincerely,
The VEKLURY team, Gilead Sciences.
|
|
|
▼This medicine is subject to additional monitoring.
*The CARAVAN trial is a single-arm, open-label study where the pharmacokinetics and safety of remdesivir in paediatric patients at least 28 days of age and weighing at least 3kg with COVID-19 (n=53) was assessed. Efficacy endpoints were secondary and descriptively analysed and therefore these should be interpreted with caution. The study is ongoing.1
† This link is to a third-party site unaffiliated with Gilead Sciences. Please abide by the terms of use of the site.
Abbreviations:
COVID-19, coronavirus disease 2019; WHO, World Health organization.
|
|
|
|
| Prescribing information can be found here for Great Britain and here for Northern Ireland.
|
|
Adverse Events should be reported:
For Great Britain and Northern Ireland, reporting forms and information can be found at https://coronavirus-yellowcard.mhra.gov.uk/ or via the Yellow card app (download from the Apple App Store or Google Play Store). Adverse events should also be reported to Gilead to safety_FC@gilead.com or +44 (0) 1223 897500.
|
|
| UK-VKY-0283 – January 2023.
|
|
| |
